A Novel Approach to Develop New and Potent Inhibitors for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease: A Computational Approach
Molecules · 2023
DOI: 10.3390/molecules28031300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Muhammad Riaz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Computational Medicinal Chemistry Laboratory, Department of Biochemistry, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan. Hauptthemen laut MEDLINE: Molecular Dynamics Simulation, Hepatitis C. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research at Umm Al-Qura University, HEC of Pakistan.
Abstract (Originalsprache)
Infection of hepatitis C (HCV) is a major threat to human health throughout the world. The current therapy program suffers from restricted efficiency and low tolerance, and there is serious demand frr novel medication. NS3/4A protease is observed to be very effective target for the treatment of HCV. A data set of the already reported HCV NS3/4A protease inhibitors was first docked into the NS3/4A protease (PDB ID: 4A92A) active sites of both protease and helicase sites for calculating the docking score, binding affinity, binding mode, and solvation energy. Then the data set of these reported inhibitors was used in a computer-based program “RECAP Analyses” implemented in MOE to fragment every molecule in the subset according to simple retrosynthetic analysis rules. The RECAP analysis fragments were then used in another computer-based program “RECAP Synthesis” to randomly recombine and generate synthetically reasonable novel chemical structures. The novel chemical structures thus produced were then docked against HCV NS3/4A. After a thorough validation of all undertaken steps, based on Lipinski’s rule of five, docking score, binding affinity, solvation energy, and Van der Waal’s interactions with HCV NS3/4A, 12 novel chemical structures were identified as inhibitors of HCV NS3/4A. The novel structures thus designed are hoped to play a key role in the development of new effective inhibitors of HCV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Computational Medicinal Chemistry Laboratory, Department of Biochemistry, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan.
- School of Biological Science, University of California, Irvine, CA 92697, USA.
- Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, P.O. Box 33, Nizwa 616, Oman.
- Substance Abuse and Toxicology Research Center, Jazan University, P.O. Box 114, Jazan 45142, Saudi Arabia.
- Medicinal and Aromatic Plants and Traditional Medicine Research Institute, National Center for Research, Khartoum P.O. Box 2404, Sudan.
- Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
ORCID-Profile: Ashfaq Ur Rehman, Muhammad Waqas, Asaad Khalid, Ashraf N Abdalla, Arif Mahmood, Abdul Wadood
Förderung
- Deanship of Scientific Research at Umm Al-Qura University
- HEC of Pakistan
Zitieren
APA
Riaz, M., Rehman, A. U., Waqas, M., Khalid, A., Abdalla, A. N., Mahmood, A., Hu, J., & Wadood, A. (2023). A Novel Approach to Develop New and Potent Inhibitors for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease: A Computational Approach. Molecules. https://doi.org/10.3390/molecules28031300
Vancouver
Riaz M, Rehman AU, Waqas M, Khalid A, Abdalla AN, Mahmood A, et al. A Novel Approach to Develop New and Potent Inhibitors for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease: A Computational Approach. Molecules. 2023. doi:10.3390/molecules28031300
BibTeX
@article{Riaz2023,
author = {Riaz, Muhammad and Rehman, Ashfaq Ur and Waqas, Muhammad and Khalid, Asaad and Abdalla, Ashraf N and Mahmood, Arif and Hu, Junjian and Wadood, Abdul},
title = {A Novel Approach to Develop New and Potent Inhibitors for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease: A Computational Approach},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28031300}
}
EUVIMED